Fibrosis: Oncodesign and TiumBio sign collaboration agreement for R&D of drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates. This initial phase of the collaboration will be funded by TiumBio.
Cyril Berthet, Pharmaco-imaging Unit Director & Director of Pharmimage 26 septembre 2019 – 17h
Exciting recent developments have proven the unique promise offered by Targeted Radionuclide Therapy (TRT) for better precision medicine. Whether given alone or in combination, TRT and immunotherapy will have an important role to play in the treatment of cancer patients in the future.
Dr. Cyril Berthet will present the tools & expertise available today for the preclinical assessment of TRT. Discover how to facilitate the translation of new targeted radionuclide therapies into clinical practice. Find out about preclinical targeted radiopharmaceuticals projects, including combination studies with chemotherapies or immune checkpoint inhibitors!
Key learning objectives
Introduction to TRT
Design & implementation of the radionuclide labeling of biological molecules of interest
Binding study to select the preclinical models and population of patients expressing the target of interest
Whole body biodistribution to evaluate the kinetic of in vivo specific binding
Evaluation of targeted radiotherapy efficacy
Benefit of radiotherapy and immunotherapy or chemotherapy combinationVitro/Vivo assays developed by Oncodesign for routine assessment of molecules.
About our speaker Cyril Berthet
Cyril Berthet is Pharmaco-imaging Unit Director & Director of Pharmimage Operations at Oncodesign. He holds a PhD in Molecular and Cellular Biology from the University of Lyon, France. In 2002, he joined the Mouse Cancer Genetics Program at the National Cancer Institute in Frederick, US as a Research Associate. He joined Oncodesign in 2007 as a project leader and now manages strategic partnerships in therapeutic and biomarker discovery. Watch the webinar
18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260